• Sign In
  • Register
  • Glossary
  • Share/Bookmark
  • RSS
All About Bleeding

Research Efforts

Novel Recombinant Hemophilia Treatments

CSL Behring’s recombinant factor development pipeline is built on its strength in protein research and development and scientific expertise in bleeding disorders

Learn more

Prof. Heimburger Award

Learn about this prestigious award for global research in coagulation. Learn More

F1000 Medical Research Posters

View information about CSL Behring posters presented at scientific symposia about Anticoagulant Reversal.
Learn more

Product Pipeline

View CSL Behring's coagulation products in development.

Learn More


CSL Behring aims to identify, develop and commercialize important new biotherapeutic products that save lives by preventing or treating serious medical conditions, including rare bleeding disorders. We are committed to significantly investing in our future research and development (R&D) portfolio and capabilities in the area of coagulation, including plasma replacement treatments and therapeutic proteins using recombinant technology. An overview of planned, current and finalized clinical trials may be found on clinicaltrials.gov. We also encourage independent research within the area of bleeding disorders by providing study grants both globally and locally.

Details about clinical studies supported by CSL Behring are available, including recruiting studies for bleeding disorders, cardiac surgery, and fibrinogen treatment.

Recombinant Factor Therapies

Research advances in our recombinant coagulation program have resulted in pre-clinical and clinical proof of principle data showing extended half-life for recombinant factor VIIa fused to recombinant albumin (rVIIa-FP), recombinant Factor VIII-Single Chain (rVIII-SingleChain) and recombinant factor IX fused to recombinant albumin (rIX-FP).

This is an extract of CSL Behring research. Visit F1000.com for additional posters.

  • Quantitative whole body autoradiography (QWBA) study on the effect of albumin fusion on the biodistribution of recombinant factor rFIX
    E Herzog, S Harris, A McEwen, I Pragst, G Dickneite, S Schulte, S Zollner F1000Posters 2014, 5: 106 (poster) Summary

  • Safety and Pharmacokinetics of a Recombinant Fusion Protein-Linking Coagulation Factor VIIa with Albumin (rVIIa-FP) in Healthy Volunteers
    A Veldman F1000Posters 2014, 5: 105 (poster) Summary

  • N-Glycosylation of rVIII-SingleChain, a novel recombinant single-chain factor VIII
    S Schmidbauer, R Witzel, L Robbel, T Weimer, H Metzner, S Schulte F1000Posters 2014, 5: 134 (poster) Summary

  • Pre-clinical safety and prolonged pharmacokinetic/pharmacodynamic (PK/PD) properties of a recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)
    S Zollner, D Schurmann, F Kaspereit, W Krege, ..., J Muller-Cohrs, I Pragst, G Dickneite, S Schulte F1000Posters 2014, 5: 124 (poster) Summary

  • Pre-clinical pharmacokinetic/pharmacodynamic (PK/PD) characteristics of rVIII-SingleChain, a novel recombinant single-chain FVIII
    S Zollner, E Raquet, A Feussner, J Müller-Cohrs, ..., T Weimer, I Pragst, G Dickneite, S Schulte F1000Posters 2014, 5: 152 (poster) Summary


Last Updated: 3/6/2015 4:19 PM
  • E-mail
  • Print
  • Share